Juventasrx.com

Waddell BJ, O’Leary PC. Distribution and metabolism of topically applied progesterone in a rat model.
Journal of Steroid Biochemistry & Molecular Biology 2002; 80: 449-455.
Stephenson K, Price C, Neuenschwander P, Kurdowska A, et al. Topical progesterone cream does not increase thrombotic and inflammatory factors in postmenopausal women. Blood 2004; 104(11): 414b-415b.
Montplaisir J, Lorrain J, et al. Sleep in menopause : differential effects of two forms of hormone replacement therapy. Menopause: The Journal of the North American Menopause Society 2001; 8(1): 10-16.
Plu-Beureau G, Le MG, et al. Percutaneous progesterone use and risk of breast cancer : results from a French cohort study of premenopausal women with benign breast disease. Cancer Detection and Prevention 19899; 23(4): 290-296.
Fitzpatrick LA, Pace C, et al. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women : a cross-sectional survey.
J of Women’s Health and Gender-based Medicine 2000; 9(4): 381-387.
Anasti JN, Leonetti HB, Wilson KJ. Topical progesterone cream has antiproliferative effect on estrogen-stimulated endometrium.
Obstet Gynecol 2001; 97( ): S10 Leonetti HB, Longo S, Anasti JN. Topical progesterone cream for vasomotor symptoms and post-menopausal bone loss. Obstet Gyneol 1999; 94: 225-228.
Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: Inverse effects on Bcl-2 and p53.
Ann Clin Lab Sci 1998; 28(6): 360-369.
Hermsmeyer RK, Rajesh G, Mishra DP, et al. Prevention of coronary hyperactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. ArteriosclerThromb Vasc. Biol 2004; 24: 955-961.
10. Cermody BJ, Arora S, et al. Progesterone inhibits human infragenicular arterial smooth muscle cell proliferation induced by high glucose and insulin concentrations. J Vasc Surg 2002; 36: 833-8.
11. Hermsmeyer K, Miyagawa K, et al. Reactivity-based coronary vasospasm independent of atherosclerosis in rhesus monkeys. J Am Coll Card 1997; 29(3): 671-80.
12. Minshall RD, Stanczyk FZ, et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys.
J Clinical Endo and Metab 1998; 83: 649-659.
13. Minshall RD, Pavcnik D, et al. Progesterone regulation of vascular thromboxane A2 receptors in rhesus monkeys.
Am J Physiol Heart Circ Physiol 2001; 281: H1498-1507.
14. Rosano GMC, Webb CM, et al. Natural progesterone, but not Medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Card 2000; 36(7): 2154-9.
15. Hermsmeyer RIK, Mishra RG, Pavcnik D, Uchida B. Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. Arterioscler Thromb VascBiol 2004; 24: 955-961.
16. Schmidt M, Renner C, Loffler G. Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts.
JEndocrinol 1998; 158(3): 401-407.
17. Brady BM, Anderson RA, et al. Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human mal. Clin Endo 2003; 58(4): 506-12.
18. Trainor BC, Bird IM, et al. Variation in aromatase activity in the medial preoptic area and plasma progesterone is associated with the onset of paternal behavior.
Neuroendocrinology 2003; 78(1): 36-44.
19. Azcoitia I, Leonelli E, et al. Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in teh sciatic nerve of aged rats.
Neurobiology of Aging 2003; 24(6): 853-60.
20. Bumke-Bogt C, Bahr V, Diederich S, et al. Expression of the progesterone receptor and progesterone- metabolizing enzymes in the female and male human kidney. J of Endocrin 2002; 175(2): 349-64.
21. Maurer M, Trajanoski Z, et al. Differential gene expression profile of glucocorticoids, testosterone, and dehydroepiandrosterone in human cells.
Horm Metab Res 2001; 2(12): 691-5.
22. Mircioiu C, Perju A, et al. Pharmacokinetics of progesterone in postmenopausal women. Eur J of Drug Metab and Pharmacokinetics. 1998; 23: 397-401.
23. DeMasi Ma. Hormonally associated migrane.
The Female Patient 2004; 29(7): 30-36.
24. Jette N, Morrell MJ. Sex-steroid hormones in women with epilepsy.
The Female Patient 2004; 29(7): 23-29.
25. Donghai, et al. Progesterone inhibits human endometrial cancer cell growth and invasiveness: downregulation of cellular adhesion molecules through progesterone B receptors. Cancer Research 2002; 62: 881-886.
26. Gruber DM, Sator MO, et al. Progesterone and neurology.
Gynecol Endocrin 1999; 13Suppl4: 41-5.
27. Sternberg WF, Chesler EJ, et al. Acute progesterone can recruit sex-specific neurochemical mechanisms mediating swim stress-induced and kappa-opioid analgesia in mice. Horm Behav 2004; 46(4): 46a7-473.
28. Unger J, Cady R, Farmer-Cady K. Migrane headaches, part 3: Hormonal factors. The Female Patient 29. Minshall RD, Pavcnik D, et al. Progesterone regulation of vascular thromboxane A2 receptors in rhesus monkeys. Am J Physiol Heart Circ Physio 2001; 281: H1498-41507.
30. Bergerson R, Demontigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. The Journal of Neuroscience 1996; 16(3): 1193-1202.
31. Ren K, Wei F, et al. Progesterone attenuates persistent inflammatory hyperalgesia in female rats: involvement of spinal NMDA receptor mechanisms.
Brain Research 2000; 865: 272-277.
32. Rosano GMC, Webb CM, et al. Natural progesterone, but nor Medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise induced myocardial ischemia in postmenopausal women.
J Am Coll Card 2000; 36(7): 2154-9.
33. Hermsmeyer RK, Mishra RG, Pavcnik D, Uchida B, et al. Prevention of coronary hyperactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. Arterioscler Thromb Vasc Biol 2004; 24: 955-961.
34. Azcoitia I, Leonelli E, et al. Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in the sciatic nerve of aged rats.
Neurobiology of Aging 2003; 24: 853-860.
35. Minshall R, Pavcnik D, et al. Nongenomic vascodilator action of progesterone on primate coronary arteries. J Appl Physiol 2002; 92: 701-708.
36. Choi BC, Polgar K, et al. Progesterone inhibits in-vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss.
Human Reproduction 2000. 15 Suppl 1: 46-59.
37. Minshall RD, Miyagawa K, Chadwick C, et al. In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones.
The FASEB Journal 1998; 12: 1419-1429.
38. Stanczyk FZ, et al. Percutaneous administration of progesterone: blood levels and endometrial protaction. Menopause 2005; 12(2): 232-237.
39. Ferrell R, O’Connor K, Rodririguez G, et al. Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in steroid hormones and menstrual cycle lengths with age. Menopause 2005; 12: 567-577.
40. Burry K, Patton P, & Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen.
American Journal of Obstetric Gynecology 1999; 180: 1504-1511.
41. Bergeron R, Montigny C, and Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors.
The Journal of Neuroscience 1996; 16: 1193-1202.
42. Wilson ME. Premature elevation in serum insulin-like growth factor-I advances first ovulation in rhesus monkeys. Journal of Endocrinology 1998; 158: 247-257.
43. Gruber DM, Sator MO, Wieser F, Worda C & Huber JC. Progesterone and neurology. Gynecol 44. Rodriguez I, Kilborn MJ, Liu XX, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001; 285: 1322-1326.
45. Minshall RD, Pavcnik D, et al. Progesterone regulation of vascular thromboxane A2 receptors in rhesus monkeys. Am J Physiol Heart Circ Physiol 2001; 281: H1498-1507.
46. Hermsmeyer RIK, Mishra RG, Pavcnik D, Uchida B. Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. Arterioscler Thromb Vasc Biol 2004; 24: 955-961.
47. Molloy EJ, O’Neill AJ, et al. Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood 2003; 102(7): 2653-9.
48. Monjo M, Rodriguez AM, et al. Direct effects of testosterone, 17 beta-estradiol, and progesterone on adrenergic regulation in cultured brown adipocytes: potential mechanism for gender-dependent thermogenesis. Endocrinology 2003; 144(11): 4923-30.
49. Unger J, Cady R, Farmer-Cady K. Migrane headaches, part 3: Hormonal factors.
The Female Patient 2003; 28(7): 31-34.
50. Sternberg WF, Chesler EJ, et al. Acute progesterone can recruit sex-specific neurochemical mechanisms mediating swim stress-induced and kappa-opiod analgesia in mice. HormBehav 2004; 46(4): 467-473.
51. Kliman HB, Keefe CL. Route of progesterone affects rates of endometrial gland dyssynchrony in donor- egg patients undergoing mock cycles.
ccessed 2/23/05.
52. Choi BC, Polgar K, Xiao L, Hill JA. Progesterone inhibits in-vitro embryotoxic TH1 cytokine production to trophoblast in women with recurrent pregnancy loss.
Human Reproduction 2000; 15 Suppl 1: 46-59.
53. Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen.
Am J Obstet Gynecol 1999; 180: 1504-11.
54. Martin VT, Behbehani M. Ovarian hormones and migrane headache: understanding mechanisms and pathogenesis. Headache 2006; 46(1): 2-23.
55. Xilouri M, Papazafiri P. Anti-apoptotic effects of allopregnanolone on P19 neurons. Eur J Neurosci 2006; 56. Dalton K. The Premenstrual Syndrome and Progesterone Therapy 2nd ed. London, England; Chicago, Ill: 57. Unger J, Cady R, Rermer-Cady K. Migraine headaches, part 3: hormonal factors.
Female Patient 2003; 28: 31-34.
58. Vliet, E. An approach to preimenopausal migraine.
Menopause Management 1995; Nov/Dec: 25-33.
59. Beynon HL, Garbett ND, Banres PJ. Severe premenstrual exacerbations of asthma: effect of intramuscular progesterone. Lancet 1988 Aug 13; 2(8607): 370-2.
60. Backstom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle.
Acta Neurol Scand 1976 Oct: 54(4): 321-47.
61. Herzog AG. Intermittent progesterone therapy and frequency of complex partial seizures in women with menstrual disorders.
Neurology 1986 Dec; 36(12): 1607-10.
62. Levine H, Watson N. Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fert Steril 2000 Mar; 73: 516-521.
63. Miles RA, Paulson RJ, Lobo RA, Press MA, Dahmoush L, Sauer MB. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study.
Fertility and Sterility 1995; 62: 485-490.
64. Taylor D. Perimenstrual symptoms and syndromes: Guidelines for symptom management and self care. Obstetrics and Gynecology 2005; 5(5): 228-241.
65. Freeman EW, Purdy RH, Coutifaris C, Rickels K, Paul SM. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers.
Neuroendocrinology 1993 Oct; 58(4): 478-84.
66. Martorano JT, Ahlgrimm M, Colbert T. Differentiating between natural progesterone and synthetic progestins: clinical implications for premenstrual syndrome and perimenopause management. Comrp Ther 1998 Jun-Jul; 24(6-7): 336-9.
67. Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Stero; 2003; 79(1): 221-222.

Source: http://juventasrx.com/Juventas/pdf/progesterone.pdf